Dr. Reddys Laboratories (RDY)
(Delayed Data from NYSE)
$14.86 USD
+0.13 (0.88%)
Updated Sep 17, 2025 04:00 PM ET
After-Market: $14.86 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Dr. Reddy's Laboratories Ltd has a PEG ratio of 6.57 compared to the Medical - Generic Drugs industry's PEG ratio of 3.52.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RDY 14.86 +0.13(0.88%)
Will RDY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for RDY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RDY
Can Tavalisse Drive Rigel's Growth Through the Rest of 2025?
ALVO Stock Trades Near 52-Week Low: Should You Buy, Hold or Sell?
RDY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Alvotech Gears Up to Report Q2 Earnings: Here's What to Expect
Dr. Reddy's Q1 Earnings Beat Estimates, Generics Sales Boost Revenues
New Strong Sell Stocks for July 18th
Other News for RDY
Is RDY set to rally? Non-ADX 1,2,3,4 Bullish shows up after climbing 0.68%
Dr. Reddy’s Launches Tegoprazan in India for Gastrointestinal Diseases
RDY forms Stochastic Sell Signal on September 15
Dr. Reddy’s Laboratories Allots Equity Shares Under Employee Stock Option Scheme
Dr. Reddy’s Laboratories Receives USFDA Observations Post-Inspection